Innoviva (INVA) EPS (Weighted Average and Diluted) (QoQ) (2010 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 40.26% |
| Jun 30, 2025 | 204.05% |
| Sep 30, 2024 | 103.64% |
| Jun 30, 2024 | -219.57% |
| Sep 30, 2023 | 4,800.00% |
| Jun 30, 2023 | -95.24% |
| Sep 30, 2022 | 5,500.00% |
| Jun 30, 2022 | -75.00% |
| Sep 30, 2021 | 0.00% |
| Jun 30, 2021 | 7.14% |
| Mar 31, 2021 | 71.43% |
| Dec 31, 2020 | 88.46% |
| Sep 30, 2020 | -62.32% |
| Jun 30, 2020 | 16.95% |
| Mar 31, 2020 | 40.48% |
| Dec 31, 2019 | 16.67% |
| Sep 30, 2019 | 5.88% |
| Jun 30, 2019 | 9.68% |
| Mar 31, 2019 | -86.75% |
| Dec 31, 2018 | 444.19% |
| Sep 30, 2018 | -12.24% |
| Jun 30, 2018 | 81.48% |
| Mar 31, 2018 | -46.00% |
| Dec 31, 2017 | 138.10% |
| Sep 30, 2017 | -30.00% |
| Jun 30, 2017 | 100.00% |
| Mar 31, 2017 | -31.82% |
| Dec 31, 2016 | 69.23% |
| Sep 30, 2016 | 0.00% |
| Jun 30, 2016 | 225.00% |
| Mar 31, 2016 | 0.00% |
| Dec 31, 2015 | 200.00% |
| Sep 30, 2013 | -18.92% |
| Jun 30, 2013 | 5.13% |
| Sep 30, 2012 | 11.90% |
| Jun 30, 2012 | -145.16% |
| Mar 31, 2012 | 306.20% |
| Dec 31, 2011 | -21.90% |
| Sep 30, 2011 | -19.35% |
| Jun 30, 2011 | -10.71% |
| Mar 31, 2011 | -4.56% |
| Dec 31, 2010 | 10.82% |
| Sep 30, 2010 | -5.76% |